Signal or Noise: What AI in Biotech is Actually Worth
March 25 @ 3:25 pm - 4:15 pm
This session looks at how AI is actually being evaluated in life science today. Rather than focusing on hype or predictions, the conversation will explore what makes the technology credible, where it is genuinely useful, and why the companies gaining traction tend to be solving fundamental problems in ways that fit real scientific and industry workflows.
- Pae Wu, General Partner – SOSV
- Marcel Frenkel, CEO – Ten63 Therapeutics
- Jason Burke, Chief AI & StrategyOfficer – Creo
- Reed Few, Director, Data Science External Innovation, R&D – Johnson & Johnson
- Dave Ousterhout, Partner – Cape Fear Bio, will help guide the discussion.